| Literature DB >> 35011527 |
Md Hridoy1,2, Md Zobayer Hossain Gorapi3, Sadia Noor3,4, Nargis Sultana Chowdhury5, Md Mustafizur Rahman6, Isabella Muscari7, Francesco Masia7, Sabrina Adorisio8, Domenico V Delfino8, Md Abdul Mazid1,4.
Abstract
Endophytic fungi are microorganisms that exist almost ubiquitously inside the various tissues of living plants where they act as an important reservoir of diverse bioactive compounds. Recently, endophytic fungi have drawn tremendous attention from researchers; their isolation, culture, purification, and characterization have revealed the presence of around 200 important and diverse compounds including anticancer agents, antibiotics, antifungals, antivirals, immunosuppressants, and antimycotics. Many of these anticancer compounds, such as paclitaxel, camptothecin, vinblastine, vincristine, podophyllotoxin, and their derivatives, are currently being used clinically for the treatment of various cancers (e.g., ovarian, breast, prostate, lung cancers, and leukemias). By increasing the yield of specific compounds with genetic engineering and other biotechnologies, endophytic fungi could be a promising, prolific source of anticancer drugs. In the future, compounds derived from endophytic fungi could increase treatment availability and cost effectiveness. This comprehensive review includes the putative anticancer compounds from plant-derived endophytic fungi discovered from 1990 to 2020 with their source endophytic fungi and host plants as well as their antitumor activity against various cell lines.Entities:
Keywords: anticancer compounds; endophytic fungi; living plants
Mesh:
Substances:
Year: 2022 PMID: 35011527 PMCID: PMC8746379 DOI: 10.3390/molecules27010296
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Discovery of anticancer agents from endophytic fungi over time.
Figure 2Relative abundance of anticancer agents from endophytic fungi.
Different cell lines against which endophytic fungal derived metabolites showed cytotoxicity.
| Cell Lines | Cell Lines | ||
|---|---|---|---|
|
| Ovarian tumor cell line |
| Human intestine cancer |
|
| Human melanoma |
| T cell leukemia |
|
| Lung carcinoma epithelial |
| Human nasopharyngeal epidermoid tumor |
|
| Skin carcinoma |
| Human leukemia cells |
|
| Renal cells |
| Mouse lymphoma cells |
|
| Human pancreatic cancer cells |
| Pancreatic carcinoma |
|
| Skin carcinoma |
| Pancreatic cancer |
|
| Human breast cancer cell line |
| Breast cancer cell line |
|
| Breast cancer |
| Human breast cancer cell line |
|
| Human hepatocellular carcinoma/human hepatoma cell line |
| Gastric cancer cells in mice |
|
| Human hepatocellular carcinoma/human hepatoma cell line |
| Breast cancer cell line |
|
| Gastric carcinoma |
| Lymphoblastic leukemia |
|
| Breast cancer cell line |
| Fibroblast-like fetal lung cells |
|
| Human breast cancer |
| Human FLT3-ITD mutant AML cell line |
|
| Chinese hamster ovary |
| Human small-cell lung cancer |
|
| Human prostate carcinoma |
| Non-small-cell lung cancer |
|
| Ehrlich ascites carcinoma |
| Colorectal neuroendocrine cell carcinoma |
|
| Human colon adenocarcinoma |
| Human ovarian cancer |
|
| Cervical cancer |
| Human pancreatic carcinoma |
|
| Human liver cancer |
| Murine leukemia cells |
|
| Human hepatocellular liver carcinoma |
| Prostate cancer |
|
| Human hepatoma cell line |
| Metastatic prostate cancer |
|
| Human gastric carcinoma |
| Mouse macrophage cell |
|
| Human promyelocytic leukemia cell line |
| CNS glioma |
|
| Human lung cancer |
| Human colon cancer cells |
|
| Normal hepatocyte |
| Colon tumor cell line |
|
| Human leukemia |
| Human colon cancer cell line |
|
| Human colorectal adenocarcinoma |
| Human pancreatic cancer cells |
|
| Colon tumor cell line |
| Bladder carcinoma |
|
| Hepatic cancer cells in mice |
| Breast cancer |
|
| Non-small-cell lung cancer cells/human lung adenocarcinoma |
| Human monocytic cell line |
|
| Non-small cell lung cancer |
| Normal human fibroblast cells |
|
| Human colon cancer line |
| Human osteosarcoma cells |
Anticancer compounds from plant-derived endophytic fungi.
| Compounds | Chemical Class | Fungal Endophytes | Host Medicinal Plant | Activity Against Cell Lines | IC50 Values | Ref. |
|---|---|---|---|---|---|---|
| Leucinostatin A | Peptide | BT-20 | 2 nM (LD50) | [ | ||
| Allantopyrone A | α-Pyrone | A549 cells, HL-60 | ˃32, 0.32 µM | [ | ||
| Alternariol, Altenusin, Alternariol 5- | Polyketide | L5178Y | ˂1 × 10−6, 1 × 10−5, 1 × 10−5, 1 × 10−5, 1 × 10−5 g/mL | [ | ||
| Lapachol | Naphtho-quinone | DU145, HepG2, Hep3B & MCF-7 | 3.5, 3.5, 3.5 & 5 µM | [ | ||
| Resveratrodehydes A & B | Stilbenoid (Resveratrol dervatives) | MDA-MB-435, | ˂10 µM | [ | ||
| Alterporriol K, Alterporriol L | Quinones |
| MDA-MB-435, | 26.97, 29.11 & 13.11, 20.04 µM | [ | |
| Alternariol-10-methyl ether | Polyketide |
|
| HL-60, A549, PC-3, HeLa, A431, | 85, ˃100, ˃100, ˃100, 95, ˃100 and ˃100 µM | [ |
| Camptothecine (CPT), | Alkaloids |
| HCT-116, | 6.59, 7.2, 10.24 µg/mL (crude fungal ethyl acetate extract) | [ | |
| Chrysin (5,7-dihydroxy flavone) | Flavone |
| MCF-7 | 34.066 µg/mL | [ | |
| Alternariol 9-methyl ether | Dibenzopyranone |
| U2OS | 28.3 µM | [ | |
| Lapachol | Naphtho-quinone |
| DU145, HepG2, Hep3B & MCF-7 | 3.5, 3.5, 3.5 & 5 µM | [ | |
| (6aR,6bS,7S)-3, 6a, 7,10-tetrahydroxy- 4,9-dioxo-4, 6a, 6b, 7, 8,9-hexahydroperylene | Perylenes |
| HCT-8 | 1.78 µM | [ | |
| 1. Flavasperone, | Naphthopyrones | 1. Hep 3B and U87 MG | 1. Between 19.92 and 47.98 µM | [ | ||
| Brefeldin A | Lactone |
| HL-60, KB, Hela, MCF-7 and Spc-A-1 | 1.0–10.0 ng/mL | [ | |
| 9-Deacetoxy fumigaclavine C | Alkaloids |
| K562 | 3.11 µM | [ | |
| 1. Fumitremorgin | Alkaloids |
| HepG2 | 1. 47.5 µM | [ | |
| 2,14-Dihydrox-7-drimen-12,11-olide | Sesquiterpenes |
| Hep-G2, MCF-7 | 61, 41.7 µg/mL | [ | |
| Nigerapyrones B, | Pyrones |
| HepG2, MCF-7, A549, SW1990, MDA-MB-231 | 86, 105, 43, 38, 48 µM | [ | |
| Rubrofusarin B | Naphtho-γ-pyrones |
|
| SW1116 | 4.5 µg/mL | [ |
| Lapachol | Naphtho-quinone |
| DU145, HepG2, Hep3B & MCF-7 | 3.5, 3.5, 3.5 & 5 µM | [ | |
| 1. Sequoiatones A & B | Polyketide |
| 1. BC | 1. 4 to 10 µM | [ | |
| Butyrolactone I and Butyrolactone V | Butenolide |
| MDA-MB-231 and MCF-7 | 34.4, 17.4 & 22.1, 31.9 µM | [ | |
| Terrein |
| A-549 | 121.9 µg/mL | [ | ||
| 1. Violaceoid A, | Hydroquinones |
| Wild Moss (Bryophyta unidentified species) | 1. HeLa, MCF-7, Jurkat, MOLT-4, HCT116, RAW264.7 | 1. 24.6, 14.8, 3.1, 3.0, 5.8, 5.6 µM (LD50) | [ |
| Taxol | Terpene |
| BT 220, H116, | - | [ | |
| Depsidone 1 | Depsidone | unidentified plant leaf of the Hala-Bala forest origin | KB, BC | 6.5, 4.1 µg/mL | [ | |
| 1. Diepoxin δ, | Spirobis-naphthalenes |
| 1. HCT-8, Bel-7402, BGC-823, A 549, A2780 | 1. 1.7, 3.3, 3.3, 3.2, 5.8 & 4.2, 2.5, 2.6, 1.6, 1.3 | [ | |
| Verticillin | Peptide |
| L5178Y | <0.1 µg/mL (EC50) | [ | |
| Ophiobolin A | Sesterterpenoid |
| Unidentified | MDA-MB-231 | 0.4–4.3 µM | [ |
| 1. Stemphyperylenol | 1. Polyketide | HCT116 | 3.13 µM | [ | ||
| Botryorhodine A and B | Depsidone |
| HeLa, K-562 | 96.97, 36.41 & 0.84, 0.003 µM (CC50) | [ | |
| Cercosporene F | Guanacastane Diterpenes | HeLa, A549, MCF-7, HCT116 and T24 | 19.3, 29.7, 46.1, 21.3 & 8.16 µM | [ | ||
| Ceriponol F, Ceriponol G, Ceriponol K | Sesquiterpenes |
|
| HeLa, HepG2, SGC7901 | 173.2, 32.3, 77.5; 185.1, ˃500.0, ˃500.0 & 47.8, 35.8, 60.2 µM | [ |
| Cochliodinol, Isocochliodinol | Quinones |
| L5178Y | 7.0, 71.5 µg/mL (EC50) | [ | |
| Chaetocochin C | Diketopiperazine | SW-480 | 0.63 µM | [ | ||
| Chaetocochin G | Indole diketo-piperazines |
| MCF-7 | 8.3 mg/mL | [ | |
| Chaetominine | Alkaloids | K562, SW1116 | 21.0, 28.0 nM | [ | ||
| Radicicol | Lactone |
| MCF-7 | 0.03 µM | [ | |
| Chaetoglobosin X | Alkaloids |
| H22, MFC | 3.125, 6.25 µg/mL | [ | |
| Chaetoglobosin C, E, F & U, | Alkaloids | KB cell line | 34.0, 40.0, 48.0 & 16.0, 48.0 µM | [ | ||
| Globosumone A & B | Ester |
|
| NCI-H460, MCF-7, SF-268, MIA Pa Ca-2, WI-38 | 6.50, 21.30, 8.80, 10.60, 13.00 & 24.80, 21.90, 29.10, 30.20, 14.20 µM | [ |
| Chaetoglobosins A, Fex, Fa & 20-dihydrochaetoglobosin | Alkaloids (cytochalasan mycotoxins) |
| HCT116 | 3.15, 4.43, 5.85, 8.44 µM | [ | |
| Anhydrofusarubin and | Naphtho-quinones | K-562 | 3.97 & 3.58 µg/mL | [ | ||
| Taxol | Diterpene |
| MCF-7, BT220, H116, INT-407, HL251, HLK210 | 0.005 to 5 µM | [ | |
| Taxol | Diterpene |
| HCT 15, T47D | 3.5, 2.5 µM | [ | |
| Taxol | Diterpene |
| MCF-7, HL 251, HLK 210, BEL7402 | 0.005 to 5 µM | [ | |
| Tyrosol C | # |
| A549, HT29, HCT116 | - | [ | |
| Deacetylcytochalasin C and Zygosporin | Cytochalasins |
| unidentified | 95-D | 3.67 & 4.04 µM | [ |
| 1. Cytospolide P, | Lactones |
| 1. A-549, QGY, U973 | 1. 2.05, 15.82, 28.26 µg/mL | [ | |
| Xylarolide | # |
| T47D | 7 µM | [ | |
| Taxol | Diterpenes | MCF-7, HL 251, HLK 210, BEL7402 | 0.005 to 5 µM | [ | ||
| Camptothecin | Alkaloids |
| A-549, HEP-2, OVCAR-5 | - | [ | |
| 1. Eutypellin A, | 1. γ-Lactone |
| NCI-H187, MCF7, KB, Vero cells | 1. 12, 84, 38, 88 µM | [ | |
| Camptothecine (CPT), | Alkaloids | HCT-116, | 5.63, 23.5, 10.32 µg/mL (crude fungal ethyl acetate extract) | [ | ||
| Beauvericin | Depsipeptide |
| PC-3, PANC-1, A549 | 49.5, 47.2, 10.4 µM | [ | |
| Taxol | Diterpenes |
| BT220, HL251, | 0.005 to 5 µM | [ | |
| Vincristine | Alkaloids |
| HeLa, MCF7, A549, U251, A431 & HEK293 | 4.2, 4.5, 5.5, 5.5, 5.8 µg/mL | [ | |
| Beauvericin | Depsipeptide |
| PC-3, PANC-1, A549 | 49.5, 47.2, 10.4 µM | [ | |
| Beauvercin | Depsipeptide |
| NCI-H460, MIA Pa Ca-2, MCF-7, SF-268, PC-3 M, MDA-MB-231, MRC-5, Hep-G2 | 1.41, 1.66, 1.81, 2.29, 3.0, 5.0, 4.7–5.0, 8.8–22.2 µM | [ | |
| Beauvercin | Depsipeptide | NCI-H460, MIA Pa Ca-2, MCF-7, SF-268, PC-3 M, MDA-MB-231 | 1.41, 1.66, 1.81, 2.29, 3.0, 5.0 µM | [ | ||
| Bikaverin | Polyketide | NCI-H460, MIA Pa Ca-2, MCF-7, SF-268, EAC, leukemia L 5178, sarcoma 37 | 1.41, 1.66, 1.81, 2.29, 0.5, 1.4, 4.2 µg/mL (ED50) | [ | ||
| Camptothecin (CPT) and 9-methoxy CPT | Alkaloids |
| HCT-116, | 7, 8.5, 8 & | [ | |
| Podophyllotoxin | Lignans |
| # | - | [ | |
| Camptothecine (CPT), | Alkaloids |
| OVCAR-5, HCT-116 | 7, 8.5, 8 & | [ | |
| Gliocladicillins A & B | Epipolythiodi-oxopiperazines | HeLa, HepG2, | 0.50, 0.50,0.20 µg/mL (GI50) | [ | ||
| Guignarenone A | Tricyclo-alternarene | KB, Vero | 0.38, 2.24 µM | [ | ||
| Guignardones Q & S | Meroterpenoids | MCF-7 | 83.7 & 92.1 µM | [ | ||
| Cajanol (5-hydroxy-3-(4- hydroxy-2-methoxyphenyl)-7-methoxychroman-4-one) | Flavonoids |
| 1. A549 | 1. 20.5 µg/mL after 72 h treatment, 24.6 µg/mL after 48 h; and 32.8 µg/mL after 24 h | [ | |
| Daldinone C & | Benzo[ | SW1116 | 49.5 & 41.0 µM | [ | ||
| 1. * Brefeldin A, trichothecolone, | * Lactone, Sesquiterpenes (trichothecenes) | KLAR 5 ( | 1. KB, BC-1, NCI-H187 | 1. 0.18, 0.04, 0.1; 12.90, 10.06, 11.31 & ˃75.10, 2.37, 1.73 µM | [ | |
| Taxol | Diterpenes |
| 1. MCF-7 | 1. 300 µg/mL | [ | |
| Lasiodiplodin | Macrolide | HCT-116 | 11.2 µg/mL | [ | ||
| Vincristine | Alkaloids | HeLa, MCF7, U251, A549, A431 & HEK293 | 4.2, 4.5, 5.5, 5.5, 5.8 µg/mL | [ | ||
| Spiromamakone A | Spirobis naphthalene |
| P388 | 0.33 µM | [ | |
| Cercosporin | Quinones |
| MCF7 | 4.68µM | [ | |
| Arundinone B | Coumarins |
| T24, A549 | 35.4, 81.6 µM | [ | |
| Mycoleptodiscin B | Alkaloids | H460, A2058, | 0.66, 0.78, 0.63, 0.60, 0.41 µM | [ | ||
| Myrotheciumone A | Lactone |
|
| HepG2, SMMC-7721, A549, MCF-7 cells, QSG-7701, HL-7702 | 5.36, 6.56, 5.88, 7.56, 16.30, 20.69 µM | [ |
| Dihydromyrothecine C | Trichothecene Macrolide |
| KB | 44.48 µM | [ | |
| Camptothecin | Alkaloids |
| A-549, HEP-2, OVCAR-5 | - | [ | |
| (2 | Pyrans | SF-268 | - | [ | ||
| Brefeldin A | Lactone | 1 | HL-60, KB, Hela, MCF-7 and Spc-A-1 | 10.0, 9.0, 1.8, 2.0 & 1.0 ng/mL | [ | |
| (22 | Steroids |
| MDA-MB435, HCT-8, SF295, HL-60 | 3.3, 14.7, 5.0, 1.6 µM | [ | |
| 1. 19-(α- | Diterpenes | HL60 | 1. 11.2 µM, | [ | ||
| Brasilamides E | Bisabolane Sesquiterpenoids | MCF-7 and MGC | 8.4 & 14.7 µM | [ | ||
| 5-Methyl-8-(3-methylbut-2-enyl) furanocoumarin | Coumarins | KB, KBV200 | 5, 10 µg/mL | [ | ||
| 1. Penicillenol A1, | Polyketides (tetramic acids derivatives) | 1. A-549, BEL-7402, P388, HL-60 | 1. 23.8, 13.03, 8.85, 0.76 µM | [ | ||
| 1. Leptosphaerone C | Polyketides | 1. A549 | 1. 1.45 µM | [ | ||
| Penifupyrone | Funicone | KB | 4.7 µM | [ | ||
| Lapachol | Naphtho-quinone | DU145, HepG2, Hep3B & MCF-7 | - | [ | ||
| Arisugacin B, Arisugacin F | Meroterpenoids | Hela, HL-60 and K562 | 59.9, 24.2, 36.2 & 44.4, 45.9, 46.6 µM | [ | ||
| 1. | 1. Heptaketide | 1,2 >> HuCCA-1, HepG2, A549, | 1,2. 5.62, 3.27, 8.01, 1.36, 4.49, 1.08, 2.81, 12.64 & 0.81, 3.41, 3.59, 0.09, 1.22, 1.00, 2.19, 3.66 µM | [ | ||
| Citriquinochroman | Alkaloids |
| L5178Y | 6.1 µM | [ | |
| 1. (+)-(3S,6S,7 R,8S)- periconone A, | Triterpenes | HCT-8, Bel-7402, BGC-823, A549, A2780, MCF-7 | ˃10−5 M | [ | ||
| Periconicin B | Diterpene |
| HeLa and CHO | 8.0 µM | [ | |
| Pestalotiopsone F | Chromone | L5178Y | 8.93 µg/mL (EC50) | [ | ||
| Pestalactam A, Pestalactam B | Alkaloids | MCF-7, NFF | 64.4, 20.2 & 58.5, 12.8 µM | [ | ||
| 1. (4 | Monoterpenoids |
| 1–4 >> HL-60 | 1–4. 15.24, 30.09, 64.87, 30.75 µM | [ | |
| Siccayne [2-(3-Methyl-3-buten-1-ynyl) Hydroquinone] | Alkyne |
| HeLa, HT29 | 48.2, 33.9 µM | [ | |
| 1. Pestalofone F, G & H, | 1. Epoxycyclo- |
| HeLa, MCF-7 | 1. 14.4, 36.4, 36.4, 16.7 & 11.9, 33.6, 33.6, 57.5 µM | [ | |
| Pestalrone B | Benzophenones |
| HeLa, HepG2, U-251 | 12.6, 31.7, 5.4 µg/mL | [ | |
| Taxol | Diterpene | Hep G2, MCF-7, BT220, HL251 | 0.5 µM | [ | ||
| Torreyanic acid | Quinones |
|
| NEC, A549 | 3.5, 45 µg/mL | [ |
| Taxol | Diterpene |
|
| BT220, H116, INT-407, HL251, HLK210, | 0.005–0.5 µM | [ |
| Taxol | Diterpenes |
| MCF-7 breast cancer cell line | 350 µg/mL | [ | |
| Photinides A–F, | γ-Lactones |
|
| MDA-MB-231 | 10 µg/mL (IC25) | [ |
| Taxol | Diterpenes |
| BT220, H116, INT-407, HL251, HLK210, | - | [ | |
| Taxol | Diterpenes | BT220, HL251, HLK 210 | - | [ | ||
| Podophyllotoxin | Lignan |
|
| Topoisomerase I | - | [ |
| Phialomustin A–D | Azaphilone |
|
| T47D | 10, 1, 7, 9.2 µM | [ |
| 1. 4-hydroxymellein | 1. Polyketide |
| P388 | 1. 94.6 (%) | [ | |
| Taxol | Diterpenes |
| MCF-7, A549, T98G | - | [ | |
| Camptothecine (CPT) | Alkaloids | HCT-116, | - | [ | ||
| 1. 2-(7′-hydroxyoxooctyl)-3-hydroxy-5-methoxybenzene-acetic acid ethyl ester | 1. Polyketide | HEp-2 and HepG2 | 32–64 µg/mL (MIC) | [ | ||
| 1. Phomopsidone A | 1. Depsidone | 1. MDA-MB-435 | 1. 63 µM | [ | ||
| Phomoxanthone A and B | Xanthone |
| KB, BC-1, Vero | 0.99, 0.51, 1.4 & 4.1, 0.70, 1.8 µg/mL | [ | |
| 1. Oblongolide Y | Polyketide | 1. BC | 1. 48 µM | [ | ||
| 18-metoxycytochalasin J, Cytochalasins H and J | Cytochalasins | HeLa | 8.18, 35.69 & 3.66 µg/mL (LC50) | [ | ||
| Dicerandrol A, B & C | Ergochromes |
| A549, HCT-116 | 7, 1.8, 1.8 & 7, 1.8, 7 µg/mL (IC100) | [ | |
| Tauranin | Sesquiterpene Quinone |
| NCI-H460, PC-3 M, MCF-7, SF-268, MIA Pa Ca-2 | 4.3, 3.5, 1.5, 1.8, 2.8 µM | [ | |
| Ergoflavin | Ergochrome | PM0651480 |
| TNF-a, IL-6, ACHN, H460, Panc1, HCT116, and Calu1 | 1.9, 1.2, 1.2, 4, 2.4, 8, & 1.5 µM | [ |
| Spiropreussione A | Spirobis naphthalene |
| A2780, BEL-7404 | 2.4, 3.0 µM | [ | |
| Cytochalasin 1, 2, 3 and E | Alkaloids | A2780S, HCT-116, | 3.91, 15.6, 3.91; 15.6, 62.5, 15.6; 3.91, -, 15.6 & ˂0.0153, 0.977, 0.244 µg/mL (IC100) | [ | ||
| 1. Rhytidones B | Spirobis | 1. CaSKi | 1. 22.81 | [ | ||
| TMC-264 | Heptaketide |
| HCT-116, HepG2, BGC-823, NCIH1650, and A2780 | 4.2, 5.9, 7.8, 3.2, 3.6 µM | [ | |
| Rhytidenone H & F | Spirobisnaphthalenes |
| Ramos and H1975 | 0.018, 0.252 & 0.048, 1.17 µM | [ | |
| 1. Secalonic acid A, Penicillixanthone A | 1. Tetrahydro-xanthone |
| Unidentified (leaf litter collected in a mangrove habitat) | MDA-MB-435 and SW-620 | 1. 0.16, 0.41 & 0.18, 0.21 µM | [ |
| Sphaeropsidin A, Sphaeropsidin D | Diterpenes | MDA-MB-231 | 1.4, 3.7 µM | [ | ||
| Taxol | Diterpenes | MCF-7, A549, T98G | - | [ | ||
| 1. Altersolanol A, | Quinones |
| 1. K562, A549, | 1. ˃1, ˃2 µM | [ | |
| 1. 3-Dehydroxymethylbisde-thio-3,10a-bis(methylthio)-gliotoxin | Alkaloids |
| B16 | 86, 82 & 78% at 500 µg/mL | [ | |
| Talaperoxide B, Talaperoxide D | Peroxides |
| MCF-7, MDA-MB-435, HepG2, HeLa, PC-3 | 1.33, 2.78, 1.29, 1.73, 0.89 & 1.92, 0.91, 0.90, 1.31, 0.70 µg/mL | [ | |
| Vincristine and Vinblastine | Alkaloids | HeLa, MCF7, U251, A549, A431 | 4.2, 4.5, 5.5, 5.5, 5.8 µg/mL | [ | ||
| Taxol | Terpenes |
| BT220, H116, INT-407, HL251, MCF-7HLK210 | - | [ | |
| Hypericin, Emodin | Polyketides |
| THP-1 | - | [ | |
| Podophyllotoxin | Lignan |
|
| Topoisomerase I | - | [ |
| Aspochalasin D, Aspochalasin J | Cytochalasan |
|
| HeLa | 5.72, 27.4 µM | [ |
| Trichothecinol-A | Mycotoxins |
| MDA-MBA-231, B16F10 | 500 µM (LC25), 500 µM (LC50) | [ | |
| Merulin A | Sesquiterpenes | XG8D | BT474, SW620 | 4.98, ˃10 & 4.84, ˃10 µg/mL | [ | |
| Eremophilanolide 1,2 & 3 | Sesquiterpenes |
| KB, MCF-7, NCI-H187, Vero cells | 3.8–21 µM | [ | |
| 1. 2-Chloro-5-methoxy-3-methylcyclohexa-2,5-diene-1,4-dione | Benzoquinone |
| Vero cells | 1.35, ˃184 µM | [ | |
| 1. Cytochalasin D | Cytochalasins | 1,2 >> NCI-H460, PC-3M, SF-268, MDA-MB-231; | D: 1.03, 0.22, 0.43, 1.01 µM; C: 1.65, 1.06, 0.96, 1.72 µM; Q: 1.53, 1.51, 1.31, 1.32; 1.44 µM | [ | ||
| Cytochalasin E | Alkaloids |
| brine shrimp | 2.79 µM (LC50) | [ | |
| 1. Cytochalasin D | 1. Cytochalasins | Unidentified | 1. NCI-H187, KB, Vero cell | 1. 5.95, 3.25, 0.36 µg/mL | [ | |
| Xylariacin A | Triterpenes | HepG2 | 48, 9.7, 46.7% at 20 µg/mL | [ | ||
| Secalonic acid D | Ergochrome | ZSU44 (not better identified) | (unidentified) mangrove plant | HL-60, K562 | 0.38, 0.43 µM | [ |
* Compounds with IC50 values less than 10 μM are reported.
Recently (2018–2020) reported potential cytotoxic metabolites isolated from medicinal-plant-associated endophytic fungi.
| Sl | Isolated Metabolites * | Fungus Name | Host Medicinal Plant | Reported Activity | References |
|---|---|---|---|---|---|
| 1 |
|
| Displayed potent cytotoxicity against cells with an IC50 value of 4.1 μM. | [ | |
| 2 |
|
| Showed selective and potent effect towards BT-549, MCF-7, SKOV-3, and HCT-116 cell lines with IC50s 0.09, 0.21, 1.23, and 0.59 μM, respectively | [ | |
| 3 | 3-(4-nitrophenyl)-5-phenyl isoxazole | Exhibited potent cytotoxic effect on HepG2 and SMCC-7721 cells with the IC50 values were 0.347 and 0.380 mM, respectively | [ | ||
| 4 |
|
| Exhibited strong biological effect against MCF7 with a half-maximal inhibitory concentration value at 7.73 ± 0.11 μM | [ | |
| 5 |
|
| Displayed cytotoxic activity against human tumor cell lines BGC-823 cells with IC50 values of 1.5 μmol·L−¹ | [ | |
| 6 |
|
| Displayed cytotoxic activity against human tumor cell lines BGC-823 cells with IC50 8.6 μmol·L−¹ | [ | |
| 7 | Xylarolide A |
| Showed promisingly inhibited growth of MIAPaCa-2 and PC-3 cells with an IC50 values of 20 14 µM | [ | |
| 8 | Jammosporin A |
|
| Exhibited promising cytotoxic potential against the human leukemia cancer cell line (MOLT-4) | [ |
| 9 |
|
| Showed potent cytotoxicity against the human ovarian cancer cell line A2780 with an IC50 value of 1.7 μM | [ | |
| 10 | Bostrycoidin |
| Significant cytotoxicity against vero cell line | [ | |
| 11 | Anhydrofusarubin | ||||
| 12 |
| Exhibited cytotoxicity against human lung adenocarcinoma EGFR-TKI-resistant A549 cells with IC50 values of 3.6 µM | [ | ||
| 13 |
| Showed activity against EGFR-TKI-resistant A549 cells with IC50 values 6.7 µM | |||
| 14 |
| Showed activity against EGFR-TKI-resistant A549 cells with IC50 values 7.8 µM | |||
| 15 | Colletotricone A |
|
| Inhibited growth of MCF-7, NCI-H460, HepG-2, and SF-268 tumor cells with IC50 values ranging from 15.7 to 46.8 μM | [ |
| 16 | Mollicellin G |
| Cytotoxic against two human cancer cell lines HepG2 and Hela withIC50 values of 19.64 and 13.97 µg/mL, respectively | [ | |
| 17 |
|
| Showed potent activity against the Hela, A549 and HepG, with IC50 values ranging from 0.17 to 14.16 nM | [ | |
| 18 |
|
| [ | ||
| 19 | Flavipin |
| Exhibited cytotoxicity toward A549, HT-29, and MCF-7 cancer cells with an IC50 concentration of 9.89 µg/mL, 18 µg/mL, and 54 µg/mL, respectively | [ | |
| 20 |
|
| Exhibited significant cytotoxicity against HL-60, A549, SMMC-7721, MCF-7, and SW480 cells with IC50 value ranged from 3.40 to 15.25 μM | [ | |
| 21 |
|
| Displayed strong to moderate cytotoxic activities against L5178Y, Ramos, and Jurkat J16 cell lines with IC50s ranging from 1.3 to 28 mM | [ | |
| 22 |
| Exhibited significant cytotoxicity with an IC50 value of 7.8 μM | [ | ||
| 23 | Asperchalasin A-F (seco-cytochalasins), Asperlactone G-H (asperlactones) | All the compounds showed cytotoxicity against A-549 with IC50 values ranging from 23.3 to 70.2 μM | |||
| 24 |
| Showed cytotoxicity against MCF-7, MDA-MB-231, H460, and HCT-8 cell lines with IC50 values ranging from 4.5 to 65 μM | [ | ||
| 25 | Chetoseminudin F ( | [ | |||
| 26 |
| [ | |||
| 27 | Pleosporalin F |
| Exhibited moderate cytotoxicity towards MDA-MB-231 cell line with an IC50 value of 22.4 ± 1.1 μM. | [ | |
| 28 | 19,20-epoxycytochalasins C ( | [ | |||
| 29 |
| [ | |||
| 30 |
| Displayed significant specific cytotoxic activity against HL-60 cells with an IC50 of 1.11 μM. | [ | ||
| 31 | Sporulosaldein F | Displayed weak cytotoxic activities against MCF-7 and LM3 cells, with IC50 values of 34.4 and 39.2 µM, respectively. | [ | ||
| 32 | Trichodermic acid |
| Displayed moderate cytotoxicity towards A549, LN229, MGC, LOVO, and MDA231 with IC50 values of 51.45, 23.43, 39.16, 46.97, and 42.85 μg/mL, respectively. | [ | |
| 33 |
| 5 showed cytotoxicity against MCF-7 and HepG-4 cell lines (IC50 values of 4.2 ± 0.6 and 7.9 ± 0.9 μM, respectively); | [ | ||
| 34 |
| Exhibited cytotoxicity against MDA-MB-435 cells (IC50 values of 5.08 ± 0.88 and 4.98 ± 0.74 μM, respectively) | [ | ||
| 35 | Phomoxanthone A (1) and Penialidin A (2) |
| [ | ||
| 36 |
|
| Exhibited prominent cytotoxic activity against all the cancer-cell lines (MDA-MB-231, T47D, MCF-7, and MIAPaCa-2 with IC50 values of 14.8, 8.12, 13.0, and 0.9 μM, respectively). | [ | |
| 37 | Myrothecines D–G ( |
| Showed cytotoxicity against K562 and SW1116 cells (IC50 values ranging between 56 nM and 16 μM). | [ | |
| 38 | Giluterrin | Exhibited cytotoxicity against 786-0 and PC-3 cell lines (IC50 of 22.93 μM and 48.55 μM, respectively). | [ | ||
| 39 | 2′-aminodechloromaldoxin ( |
| 1 & 2 displayed moderate cytotoxicity against NCI-H460, SF-268, MCF-7 and PC-3cell lines (IC50 values of 18.63, 20.23, 23.53, 20.48 μM and 16.47, 17.57, 20.79, 19.43 μM, respectively). | [ | |
| 40 |
| Showed cytotoxicity against MDA-MB-231 and U-2OS cells (IC50 values ranging between 4.5 to 21.7 μM). | [ | ||
| 41 | ( |
| [ | ||
| 42 | Flavoglaucin | Exhibited most potent cytotoxicity against Caco-2 cells (IC50 of 2.87 μM) | [ | ||
| 43 |
| [ | |||
| 44 |
| [ | |||
| 45 |
| [ | |||
| 46 | Lithocarin B & C, Tenellone H | Displayed weak inhibitory activities against SF-268, MCF-7, HepG-2, and A549 cell lines with IC50 values ranging between 30 and 100 μM | [ | ||
| 47 | All Showed significant cytotoxicity against the cell lines, L929 and KB-3-1 (IC50 values ranging from 2.4 to 26 μg/mL) | [ | |||
| 48 |
|
| [ | ||
| 49 |
|
|
| [ | |
| 50 | Koninginol B ( | [ | |||
| 51 | Cytochalasin D1 (1) and C1 (2) | [ | |||
| 52 |
| [ | |||
| 53 |
| Exhibited cytotoxicity against HT-29, HepG2, Caco-2, HeLa, IEC6, and vero cells (IC50 values ranging between 8 to 23.5 μM) | [ | ||
| 54 | Chloroisosulochrin | Exhibited moderate cytotoxicity towards the HeLa cell line with an IC50 value of 35.2 μM | [ | ||
| 55 | Pestalotether D | Exerted cytotoxicity against HeLa and MCF-7 cell lines with IC50 values of 60.8 and 22.6 M, respectively | |||
| 56 |
|
| Exhibited potent cytotoxicity towards mouse lymphoma cell line L5178Y with an IC50 value of 3.0 μM | [ | |
| 57 | Terezine E and 14-hydroxyterezine D |
| Showed potent activity against K-562 and HUVEC cell lines | [ | |
| 58 | Citrinin (CIT) and dicitrinin-A |
|
| Showed toxicity in | [ |
| 59 | Allantopyrone E |
| Showed cytotoxic effect on HeLa cells with IC50 = 50.97 μM | [ | |
| 60 |
| Both compounds showed promising cytotoxicity towards HepG2 Cells with IC50 values of 5.98 ± 0.12 µM and 9.97 ± 0.06 µM, respectively | [ | ||
| 61 |
|
|
| Potent cytotoxic activities against human pancreatic cancer cells, including AsPC-1, SW1990 and PANC-1 cells, with IC50 values ranging from 1.2 to 15.6 μM | [ |
| 62 |
| showed moderate to strong cytotoxicity towards A549, BT-549, HepG2, and MCF-7 cells with IC50 values ranging from 5.6 to 14.2 µM | [ | ||
| 63 | Methyl 3-chloroasterric acid | Exhibited cytotoxicity against MDA-MB-435 cell with an IC50 of 25.96 ± 0.32 μM | [ | ||
| 64 | Rhizoperemophilane N |
|
| Exhibited selective cytotoxicity against NCI-H1650 and BGC823 tumor cells | [ |
| 65 |
|
| exhibited strong cytotoxic activities against human lymphoma (Ramos) and leukemia (Jurkat J16) cells with IC50 values of 4.7 and 4.4 μM, respectively | [ | |
| 66 |
|
|
| Both the compounds exhibited promising cytotoxicity against SF-268, NCI-H460, and HepG-2 tumor cell lines with the IC50 ranging from 0.0002–16.2 μM and induced apoptosis of HepG-2 cells | [ |
| 67 | Colletotrichalactone A and colletotrichalactone Ca |
| Exhibited moderate-to-potent cytotoxic activities against MCF7 cells with IC50s of 35.06 and 25.20 µM, respectively | [ | |
| 68 | Emodin, (an anthraquinone) |
|
| exhibited cytotoxicity against murine leukemia P-388 cells with an IC50 value of 0.41 μg/mL | [ |
| 69 |
| Showed cytotoxicity against the A549 and HepG2 cell with IC50 values of 5.34 and 12.03 μM, respectively | [ | ||
| 70 | Demethylincisterol A5 | Showed cytotoxicity against the A549 and HepG2 cell with IC50 values of 11.05 and 19.15 μM, respectively |
* Compounds with IC50 values less than 10 μM are reported in bold.
Figure 3Anticancer compounds of different chemical classes from endophytic fungi-alkaloidal compounds and their derivatives: (a) (1–8), benzo[j]fluoranthene (9), Chromone (10), coumarin (11), depsidones (12, 13), depsideptide (14), ergochromes (15, 16), ester (17), lactones (18–22), lignans (23–24), peptide (25), polykedites (26); (b) polyketides (27–32), quinones (33–39), spirobisnaphthalenes (40–42), terpenes (43–54), xanthones (55), naphthoquinones (56, 57).
Figure 4Fusarubin (FUS) and FUS analogues with proposed mechanism of action. (A) Structures of FUS derivatives and (B) Proposed mechanism of action of FUS on OCI-AML3 cells.